Project HERO: Health Empowerment & Recovery Outcomes
NCT03345563
Bladder Cancer, Colon Cancer
New Brunswick, New Jersey, United States
View Trial DetailsNCT Number: NCT03771508
Observational, Multicenter, Post-market, Minimal risk, Prospective data collection of PillCam SB3 videos (including PillCam reports) and raw data files and optional collection of Eneteroscopy reports
Looking for future studies?
Notify MeAll sexes
Observational
Birmingham Gastroenterology Associates, Birmingham, Alabama, United States
Up to 8000 PillCam SB3 videos (including PillCam reports) and raw data files will be collected in up to 50 medical centers in the US. Study duration is up to 7 years from IRB approval.
Medical center study sites will provide relevant videos (including PillCam reports) and raw data from patients who underwent SB3 procedures.
Per patient demographic data will be also collected to provide a description of the study population characteristics and disposition.
Additional Standard of care data collection might be performed (optional). This data will include a de-identified Eneteroscopy report, from patients enrolled to the study and referred to Eneteroscopy procedure (all types of Eneteroscopies), following findings identified during the PillCamTM SB procedure, as part of the standard of care procedure. This data might be collected retrospectively for enrolled patients who underwent an Eneteroscopy procedure. The de-identified reports will be used by MDT GI research and development team to further develop and validated SB capsule localization.
Study subjects will not undergo any additional procedures, nor will their diagnosis and subsequent treatment pathway be changed for the purpose of the registry.
The data will be used by MDT GIs research and development team for the development and validation of improved and new detectors in the PillCam software.
The videos (including PillCam reports) and raw data files will be de-identified at the medical center by representatives who are authorized and delegated to review medical records, prior to providing them to the sponsor. All data in the study- videos, reports, raw data files and demographic information will be de-identified in a manner that is untraceable by the sponsor clinical study team members.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Up to 7 years from study approval
sponsor database will be expanded with images of pathologies and normal mucosa for future development and validation of improved algorithms for GI pathologies detection with the PillCam platform
Medtronic - MITG
Industry
PillCam SB3 Registry for Development and Validation of Improved Algorithms for GI Pathologies Detection
Acronym: SODA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03345563
Bladder Cancer, Colon Cancer
New Brunswick, New Jersey, United States
View Trial DetailsNCT06582849
Adnexal Diseases, Anal Cancer
St Louis, Missouri, United States
View Trial DetailsNCT00445965
Adnexal Diseases, Astrocytoma
New York, United States
View Trial DetailsNCT04476082
Bile Duct Cancer, Bile Duct Diseases
Greifswald, Germany
View Trial Details